Shares of drug maker Epizyme, Inc. (EPZM) are falling more than 18% Friday morning at $11.02 after the company reported wider loss for the third quarter.
Net loss for the quarter widened to $56.07 million, or $0.55 per share from $36.09 million or $0.40 per share loss a year ago.
Revenue for the third quarter declined to $3.57 million from $5.72 million last year.
In a separate release, Epizyme announced expanded loan facility with Pharmakon Advisors, an affiliate of Royalty Pharma, for additional $150 Million to fund its growth initiatives.
Epizyme and Pharmakon Advisors originally executed their agreement in November last year and the company had drawn $70 million.
The stock has been trading in the range of $9.90- $27.82 in the last one year.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.